Skip to main content

Dosage and Administration

Weight-Based Dosing and OPTION TO
ADMINISTER at Home or in Office1

Not an actual patient.

Not an actual patient.

Available in a 200 mg and 300 mg pre-filled pen (for indicated patients 2+ years of age)
or pre-filled syringe (for indicated patients 1+ year of age) FOR SUBCUTANEOUS INJECTION1

  • DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider
  • A caregiver or patient 12 years of age and older may inject DUPIXENT after training in subcutaneous injection technique using
    the pre-filled syringe or pre-filled pen
  • In children 12 years of age and older, it is recommended that DUPIXENT be given by or under the supervision of an adult
  • In children 1 year to less than 12 years of age, DUPIXENT should be given by a caregiver
  • Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use, according to the
    Instructions for Use
  • Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with
    DUPIXENT

WEIGHT-BASED DOSING FOR EoE PATIENTS1

1+ YEAR OF AGE

No loading dose

15 to <30 kg

Every 2 weeks

200 mga

1 pre-filled pen or syringe

30 to <40 kg

Every 2 weeks

300 mgb

1 pre-filled pen or syringe

≥40 kgc

Every week

300 mgb

1 pre-filled pen or syringe

a200 mg=1.14 mL solution.

b300 mg=2 mL solution.

cThe recommended dosage of 300 mg QW for pediatric subjects 1 to 11 years of age weighing ≥40 kg is based on modeled pharmacokinetic data to provide comparable exposures to the 300 mg QW dosage in adult and pediatric subjects 12 years of age and older weighing ≥40 kg with EoE.

HEAR FROM A PROVIDER:
DR. joshua wechsler, md, MSCI

Listen to Dr. Wechsler’s insight for helping pediatric patients
articulate their symptoms.

Speaker Profile

Dr. Wechsler, MD, MSCI

There’s some patients where the self-injection is a bit of a challenge, and for them maybe having a family member help them with it can be really, really helpful. For others, if it’s more the anticipation of the discomfort, we talk about trying to do things that can really calm the moment—music, certain types of videos or games or experiences—talking through things that can really help distract you from that experience.

administration options1,2

important administration instructions1

See the Instructions for Use for more detailed instructions on the
preparation and administration of DUPIXENT

  • Patients and/or caregivers should read the Instructions for Use prior to injecting
  • Instruct patients and/or caregivers to administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
  • The upper arm can also be used if a caregiver administers the injection
  • It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
Human body diagram of ideal Dupixent® (dupilumab) administration sites including outer upper arms, abdomen, and thighs

Pre-filled Pen

Instructions for Use - 200 mg
Instructions for Use - 300 mg

Pre-filled Syringe

Instructions for Use - 200 mg
Instructions for Use - 300 mg

Supplemental Injection Training

VIEW PATIENT VIDEOS

Missed dose information1

  • If a weekly dose is missed, administer the dose as soon as possible, and start a new weekly schedule from the date of the last administered dose
  • If an every-2-week dose is missed, administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, administer the dose, starting a new schedule based on this date

Preparation for use1

Before injection, instruct patients and/or caregivers to remove DUPIXENT from the refrigerator and allow DUPIXENT to reach room temperature without removing the needle cap.

  • 45 minutes for the 300 mg/2 mL (150 mg/mL) pre‑filled syringe or pre-filled pen
  • 30 minutes for the 200 mg/1.14 mL 
(175 mg/mL) pre-filled syringe or pre-filled pen

Patients and/or caregivers should inspect 
DUPIXENT visually for particulate matter 
and discoloration prior to administration.

  • Do not use if the liquid contains visible particulate matter or is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow)

Patients and/or caregivers should discard any unused product remaining in the pre‑filled syringe or pre-filled pen in accordance with local requirements.

STORAGE AND HANDLING1

  • DUPIXENT is sterile and preservative-free. Patients and/or caregivers should discard any unused portion
  • Patients and/or caregivers should store DUPIXENT by refrigerating at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect from light
  • If necessary, DUPIXENT may be kept at room temperature up to 77 °F (25 °C) for a maximum of 14 days. DUPIXENT should not be
    stored above 77 °F (25 °C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded
  • DUPIXENT should not be exposed to heat or direct sunlight
  • Any unused medicinal product or waste material should be disposed of in accordance with local requirements
  • Do NOT freeze. Do NOT shake

Check formulary status in your area

See insurance coverage status, prior authorization, and step edit information for DUPIXENT.

LOOK UP COVERAGE

Help Patients Start and Stay on DUPIXENT

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT, offering financial assistance for eligible patients, one-on-one nursing support, and more.

EXPLORE DUPIXENT MyWay